{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:08:35Z","timestamp":1793642915388,"version":"4.5.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Translational Research Grant of HCRCH","award":["2020ZKMB06"],"award-info":[{"award-number":["2020ZKMB06"]}]},{"name":"Xingliao Talents Program","award":["xlyc1807265"],"award-info":[{"award-number":["xlyc1807265"]}]},{"name":"Liaoning Province Central Guidance Special Project for Local Science and Technology Development","award":["2023JH6\/100200006"],"award-info":[{"award-number":["2023JH6\/100200006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04139-5","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T16:13:15Z","timestamp":1749226395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early replacement of re-induction therapy following failed intensive induction treatment enhances the therapeutic efficacy of newly diagnosed AML"],"prefix":"10.1038","volume":"15","author":[{"given":"Jingchen","family":"Sui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"4139_CR1","unstructured":"Yates, J. W., Wallace, H. J. Jr, Ellison, R. R. & Holland, J. F. Cytosine arabinoside (NSC-63878) and Daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep. 57 (4), 485\u2013488 (1973)."},{"issue":"13","key":"4139_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez, H. F. et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl. J. Med. 361 (13), 1249\u20131259 (2009).","journal-title":"N Engl. J. Med."},{"issue":"2","key":"4139_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood.V60.2.454.454","volume":"60","author":"J Yates","year":"1982","unstructured":"Yates, J. et al. Cytosine arabinoside with Daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60 (2), 454\u2013462 (1982).","journal-title":"Blood"},{"issue":"14","key":"4139_CR4","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2011-06-361410","volume":"118","author":"JH Lee","year":"2011","unstructured":"Lee, J. H. et al. Cooperative study group A for hematology. A randomized trial comparing standard versus high-dose Daunorubicin induction in patients with acute myeloid leukemia. Blood 118 (14), 3832\u20133841 (2011).","journal-title":"Blood"},{"issue":"25","key":"4139_CR5","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett, A. K. et al. A randomized comparison of Daunorubicin 90\u00a0mg\/m2 vs 60\u00a0mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125 (25), 3878\u20133885 (2015).","journal-title":"Blood"},{"issue":"16","key":"4139_CR6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","volume":"18","author":"T Murphy","year":"2017","unstructured":"Murphy, T. & Yee, K. W. L. Cytarabine and Daunorubicin for the treatment of acute myeloid leukemia. Expert Opin. Pharmacother. 18 (16), 1765\u20131780 (2017).","journal-title":"Expert Opin. Pharmacother"},{"issue":"24","key":"4139_CR7","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2017.72.8618","volume":"35","author":"JH Lee","year":"2017","unstructured":"Lee, J. H. et al. Cooperative study group A for hematology. Prospective randomized comparison of Idarubicin and High-Dose Daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 35 (24), 2754\u20132763 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"4139_CR8","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","volume":"30","author":"J Holowiecki","year":"2012","unstructured":"Holowiecki, J. et al. Cladribine, but not fludarabine, added to Daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J. Clin. Oncol. 30 (20), 2441\u20132448 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"4139_CR9","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Venetoclax plus 3\u2009+\u20097 Daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 9 (6), e415\u2013e424 (2022).","journal-title":"Lancet Haematol."},{"issue":"7","key":"4139_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl. J. Med. 383 (7), 617\u2013629 (2020).","journal-title":"N Engl. J. Med."},{"issue":"24","key":"4139_CR11","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135 (24), 2137\u20132145 (2020).","journal-title":"Blood"},{"issue":"2","key":"4139_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea, D. A. et al. Venetoclax with Azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am. J. Hematol. 96 (2), 208\u2013217 (2021).","journal-title":"Am. J. Hematol."},{"issue":"10","key":"4139_CR13","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 7 (10), e724\u2013e736 (2020).","journal-title":"Lancet Haematol."},{"issue":"15","key":"4139_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei, A. H. et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J. Clin. Oncol. 37 (15), 1277\u20131284 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"4139_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-023-00409-y","volume":"12","author":"X Suo","year":"2023","unstructured":"Suo, X. et al. Venetoclax combined with Daunorubicin and cytarabine (2\u2009+\u20096) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial. Exp. Hematol. Oncol. 12 (1), 45 (2023).","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"4139_CR16","doi-asserted-by":"publisher","first-page":"2343604","DOI":"10.1080\/16078454.2024.2343604","volume":"29","author":"H He","year":"2024","unstructured":"He, H., Wen, X. & Zheng, H. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis. Hematology 29 (1), 2343604 (2024).","journal-title":"Hematology"},{"issue":"12","key":"4139_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140 (12), 1345\u20131377 (2022).","journal-title":"Blood"},{"issue":"2","key":"4139_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00277-023-05096-7","volume":"102","author":"W Fu","year":"2023","unstructured":"Fu, W. et al. Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment. Ann. Hematol. 102 (2), 329\u2013335 (2023).","journal-title":"Ann. Hematol."},{"issue":"4","key":"4139_CR19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/annonc\/mdr346","volume":"23","author":"U Brunnberg","year":"2012","unstructured":"Brunnberg, U. et al. Induction therapy of AML with ara-C plus Daunorubicin versus ara-C plus Gemtuzumab Ozogamicin: a randomized phase II trial in elderly patients. Ann. Oncol. 23 (4), 990\u2013996 (2012).","journal-title":"Ann. Oncol."},{"issue":"2","key":"4139_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/leu.2013.290","volume":"28","author":"C R\u00e9cher","year":"2014","unstructured":"R\u00e9cher, C. et al. Groupe Ouest-Est d\u2019 \u00e9tude des Leuc\u00e9 Mies Aigu\u00ebs et autres. Long-term results of a randomized phase 3 trial comparing Idarubicin and Daunorubicin in younger patients with acute myeloid leukaemia. Leukemia 28 (2), 440\u2013443 (2014).","journal-title":"Leukemia"},{"issue":"16","key":"4139_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","volume":"16","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig, C. et al. Study alliance leukaemia. Addition of Sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 16 (16), 1691\u20131699 (2015).","journal-title":"Lancet Oncol."},{"issue":"11","key":"4139_CR22","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"G Borthakur","year":"2022","unstructured":"Borthakur, G. et al. Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with Gemtuzumab Ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am. J. Hematol. 97 (11), 1427\u20131434 (2022).","journal-title":"Am. J. Hematol."},{"issue":"22","key":"4139_CR23","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1002\/cncr.30883","volume":"123","author":"E Jabbour","year":"2017","unstructured":"Jabbour, E. et al. A randomized phase 2 study of Idarubicin and cytarabine with Clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123 (22), 4430\u20134439 (2017).","journal-title":"Cancer"},{"issue":"27","key":"4139_CR24","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett, A. K. et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research Council AML15 trial. J. Clin. Oncol. 31 (27), 3360\u20133368 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"4139_CR25","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/sj.leu.2404287","volume":"20","author":"J Jin","year":"2006","unstructured":"Jin, J. et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de Novo acute myeloid leukemia. Leukemia 20 (8), 1361\u20131367 (2006).","journal-title":"Leukemia"},{"issue":"10","key":"4139_CR26","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1007\/s00277-023-05400-5","volume":"102","author":"W Duan","year":"2023","unstructured":"Duan, W. et al. Comparison of efficacy between Homoharringtonine, aclarubicin, cytarabine (HAA) and Idarubicin, cytarabine (IA) regimens as induction therapy in patients with de Novo core binding factor acute myeloid leukemia. Ann. Hematol. 102 (10), 2695\u20132705 (2023).","journal-title":"Ann. Hematol."},{"issue":"8","key":"4139_CR27","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/ajh.26601","volume":"97","author":"CD DiNardo","year":"2022","unstructured":"DiNardo, C. D. et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am. J. Hematol. 97 (8), 1035\u20131043 (2022).","journal-title":"Am. J. Hematol."},{"issue":"8","key":"4139_CR28","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia, T. M. et al. Venetoclax plus intensive chemotherapy with Cladribine, Idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 8 (8), e552\u2013e561 (2021).","journal-title":"Lancet Haematol."},{"issue":"4","key":"4139_CR29","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/jha2.792","volume":"4","author":"BQ Song","year":"2023","unstructured":"Song, B. Q. et al. Outcomes of venetoclax combined with Homoharringtonine and cytarabine in fit adults patients with de Novo adverse-risk acute myeloid leukaemia: a single-centre retrospective analysis. EJHaem 4 (4), 1208\u20131211 (2023).","journal-title":"EJHaem"},{"issue":"2","key":"4139_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbmt.2014.09.022","volume":"21","author":"RB Walter","year":"2015","unstructured":"Walter, R. B. et al. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol. Blood Marrow Transpl. 21 (2), 373\u2013378 (2015).","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"5","key":"4139_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.amjms.2016.02.034","volume":"351","author":"S Wu","year":"2016","unstructured":"Wu, S. et al. Prognosis of patients with de Novo acute myeloid leukemia resistant to initial induction chemotherapy. Am. J. Med. Sci. 351 (5), 473\u2013479 (2016).","journal-title":"Am. J. Med. Sci."},{"issue":"1","key":"4139_CR32","doi-asserted-by":"publisher","first-page":"2310960","DOI":"10.1080\/16078454.2024.2310960","volume":"29","author":"J Ding","year":"2024","unstructured":"Ding, J. et al. Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China. Hematology 29 (1), 2310960 (2024).","journal-title":"Hematology"},{"issue":"1","key":"4139_CR33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12885-020-07222-4","volume":"20","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients. BMC Cancer. 20 (1), 732 (2020).","journal-title":"BMC Cancer"},{"issue":"11","key":"4139_CR34","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","volume":"33","author":"X Chen","year":"2015","unstructured":"Chen, X. et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J. Clin. Oncol. 33 (11), 1258\u20131264 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"4139_CR35","first-page":"177","volume":"38","author":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association","year":"2017","unstructured":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017). Zhonghua Xue Ye Xue Za Zhi. 38 (3), 177\u2013182 (2017). Chinese.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"4139_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129 (4), 424\u2013447 (2017).","journal-title":"Blood"},{"issue":"16","key":"4139_CR37","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1200\/JCO.2004.99.116","volume":"22","author":"U Creutzig","year":"2004","unstructured":"Creutzig, U. & Kaspers, G. J. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 22 (16), 3432\u20133433 (2004).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04139-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04139-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04139-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T16:13:17Z","timestamp":1749226397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04139-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4139"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04139-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies were approved by the First Hospital of China Medical University Ethics Committee. The studies were conducted in accordance with the local legislation and institutional requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"20022"}}